Manufacturers report benefit with cemiplimab in clinical trial

In a phase II study in advanced basal cell carcinoma that had progressed despite previous hedgehog pathway inhibitor therapies, cemiplimab, a PD-1 checkpoint inhibitor, was found to have an objective response rate of 29%, with an estimated duration for response >1 year of 85%.

Biospace Inc.